编者按：2026年美国临床肿瘤学会年会（ASCO 2026）将于5月29日至6月2日在旧金山举行。作为全球肿瘤领域的顶尖学术盛会，本届会议汇聚了众多权威专家，分享了最新前沿进展。大会围绕前列腺癌、尿路上皮癌、肾癌等泌尿肿瘤领域公布了43项口头报告（含5项LBA），展示了该领域的最新突破。肿瘤瞭望-泌尿时讯特别整理（如有遗漏和错误，欢迎留言补充），以飨读者。

01
肾癌领域

摘要号：4500

英文标题：A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM)：RADICAL (Alliance A031801).

中文标题：一项针对患有肾细胞癌骨转移患者的2期随机试验，研究了镭223和卡博替尼的疗效：RADICAL (Alliance A031801)

讲者：Rana R. McKay教授

单位：UC San Diego Moores Cancer Center

摘要号：4501

英文标题：A prospective, mult -center, phase lb/II trial of first-line cadonilimab plus axitinib in advanced non-clear cell renal cell carcinoma

中文标题：一项前瞻性、多中心、I/II期临床试验，分析了卡度尼利单抗联合阿昔替尼一线治疗晚期非透明细胞肾细胞癌的疗效

讲者：胡旭教授

单位：四川大学华西医院

摘要号：4502

英文标题：ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial

中文标题：在KEYNOTE-564试验中，对接受帕博利珠单抗或安慰剂辅助治疗的肾细胞癌患者进行ctDNA分析

讲者：Toni K. Choueiri教授

单位：Dana-Farber Cancer Institute, Harvard Medical School

摘要号：LBA4511

英文标题：Durvalumab monotherapy versus active monitoring for resected primary renal cell carcinoma in RAMPART： An international, phase 3, randomized controlled trial.

中文标题：RAMPART研究：度伐利尤单抗单药治疗与主动监测治疗切除的原发性肾细胞癌：一项国际性3期随机对照试验

讲者：James M. Larkin教授

单位：The Royal Marsden NHS Foundation Trust

摘要号：4512

英文标题：Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma.

中文标题：肾细胞癌辅助治疗帕博利珠单抗后的决策后悔分析和毒性感知

讲者：Elizabeth Nally教授

单位：Barts Cancer Institute

摘要号：4519

英文标题：Microbial dysbiosis as predictor of beneftfrom CBM58s as an aduncto immune checkpoint blockade (CB)-based first line therapies in metastatic renal cell carcinoma (mRCC)

中文标题：微生物菌群失调作为转移性肾细胞癌一线免疫检查点阻断辅助疗法疗效的预测指标

讲者：Rahul Winayak教授

单位：City of Hope Comprehensive Cancer Center, Duarte, CA, Beth Israel Deaconess Medical Center

摘要号：4520

英文标题：Prospective clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC)： A collaborative multi-institutional study.

中文标题：基于panitumumab的EGFR阻断治疗SMARCB1缺陷型肾髓质癌(RMC)的前瞻性临床活性和临床前基础：一项多机构合作研究

讲者：Pavlos Msaouel教授

单位：Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center

摘要号：4521

英文标题：Final results of a phase 2 trial of cabozantinib plus nivolumab (CaboNivo) in patients with non-clear cell renal cell carcinoma (nccRCC).

中文标题：卡博替尼联合纳武利尤单抗治疗非透明细胞肾细胞癌（nccRCC）患者的2期试验的最终结果

讲者：Darren R. Feldman教授

单位：Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College

02
尿路上皮癌领域

摘要号：4503

英文标题：Intravesical recombinant BCG combined with chemo-immunotherapy (chemo-IO) as perioperative therapy for patients with muscle-invasive bladder cancer (MIBC)： Primary analysis of SAKK 06/19.

中文标题：膀胱内BCG联合化疗免疫疗法作为肌层浸润性膀胱癌患者的围手术期治疗策略：SAKK 06/19的初步分析

讲者：Richard Cathomas教授

单位：Division of Oncology, Cantonal Hospital Graubunden

摘要号：4504

英文标题：Feasibility and safety results from RAD-IO： A multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.

中文标题：RAD-IO的可行性和安全性结果：一项多阶段试验，评估度伐利尤单抗联合5-氟尿嘧啶和丝裂霉素C化疗放疗治疗肌层浸润性膀胱癌患者的疗效

讲者：Nicholas D. James教授

单位：The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust

摘要号：4506

英文标题：Perioperative SHR-A2102, a novel nectin-4–targeted antibody-drug conjugate, in combination with adebrelimab for patients (pts) with muscle-invasive bladder cancer： Results from a phase 2/3 study.

中文标题：围手术期SHR-A2102（一种新型的nectin-4靶向抗体偶联药物）与阿得贝利单抗联合用于治疗肌层浸润性膀胱癌患者：一项2/3期研究的结果

讲者：叶定伟教授

单位：复旦大学附属肿瘤医院

摘要号：4507

英文标题：Enfortumab-vedotin plus pembrolizumab (EV+P) vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma(la/mUC)：3.5year follow-up and response analyses from the phase 3 EV-302 study

中文标题：维恩妥尤单抗联合帕博利珠单抗对比化疗在既往未接受治疗的局部晚期或转移性尿路上皮癌患者中的分析：EV-302 3期研究的3.5年随访和疗效分析

讲者：Thomas Powles教授

单位：Barts Cancer Centre, Queen Mary University of London

摘要号：4508

英文标题：Initial results from NEXUS-01,a phase 1 study of LY4052031, an antibody drug conjugate targeting Nectin-4,in participants with advanced or metastatic urothelial carcinoma

中文标题：NEXUS-01是一项针对晚期或转移性尿路上皮癌患者的1期研究，旨在评估LY4052031（一种靶向Nectin-4的抗体偶联药物）的疗效

讲者：Gopa lyer教授

单位：Department of Medicine, Memorial Sloan Kettering Cancer Center

摘要号：4510

英文标题：Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible： Phase 3 KEYNOTE-905 study

中文标题：一项针对不适合接受顺铂治疗的肌层浸润性膀胱癌患者，评估新辅助和辅助维恩妥尤单抗联合帕博利珠单抗治疗的健康相关生活质量：III期KEYNOTE-905研究

讲者：Peter H. O'Donnell教授

单位：University of Chicago, Chicago, L, Indiana University Melvin and Bren Simon Comprehensive Cancer Center

摘要号：4513

英文标题：Health-related quality of life (HRQOL) with pembrolizumab or observation for high-risk muscle-invasive urothelial carcinoma after surgery： Results from the AMBASSADOR randomized trial (Alliance A031501).

中文标题：术后通过帕博利珠单抗或观察治疗高危肌层浸润性尿路上皮癌的健康相关生活质量：AMBASSADOR随机试验(Alliance A031501)的结果

讲者：Ronald C. Chen教授

单位：University of Kansas Medical Center, Kansas City, KS, Department of Quantitative Health Sciences, Mayo Clinic Arizona

摘要号：4514

英文标题：MAIN-CAV： Phase Il randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC

Alliance A032901)

中文标题：MAIN-CAV：一项II期随机试验，比较卡博替尼和阿维鲁单抗维持治疗与一线铂类化疗后单独使用阿维鲁单抗治疗局部晚期/转移性尿路上皮癌患者的疗效：Alliance A032901

讲者：Shilpa Gupta教授

单位：Department of Hematology and Oncology, Cleveland Clinic - Taussig Cancer Institute

摘要号：4516

英文标题：Interim analysis results from Duravelo-2： Zelenectide pevedotin (zele BT8009) + pembrolizumab in patients (pts) with previously untreated locally advanced/metastatic urothelial carcinoma (la/mUC)

中文标题：Duravelo-2中期分析结果：Zelenecide pevedotin (zele BT8009) +帕博利珠单抗治疗既往未接受治疗的局部晚期/转移性尿路上皮癌患者

讲者：Yohann Loriot教授

单位：University Paris Saclay, Gustave Roussy

摘要号：4517

英文标题：Initial results from EXCEED, a phase 1 study of LY4101174,an antibody drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma.

中文标题：EXCEED是一项针对晚期或转移性尿路上皮癌患者的1期研究，使用LY4101174（一种靶向Nectin-4的抗体偶联药物）的初步结果

讲者：Xin Gao教授

单位：Massachusetts General Hospital, Harvard Medical School

摘要号：4518

英文标题：Buumtatug fvedoin (BFy,9MW2821) plus toripalimab in patients with localy advanced or metastatic urothelial carcinoma (a/mUC)： Folowup resuits from a phase 1b/2 study

中文标题：Buumtatug fvedoin (BFy,9MW2821)联合特瑞普利单抗治疗局部晚期或转移性尿路上皮癌患者：一项1b/2期研究的随访结果

讲者：盛锡楠教授

单位：北京大学肿瘤医院

摘要号：4624

英文标题：Durvalumab(D) in combination with BCG induction and maintenance (1 + M) therapy for BCG-naive, high-riskDurvalumab non-muscle-invasive bladder cancer (NMIBC)： 5 year overall survival (OS) analysis and patent-reported outcomes (PROs) from POTOMAC.

中文标题：度伐利尤单抗联合BCG诱导和维持方案用于BCG初治、高危非肌层浸润性膀胱癌(NMIBC)：POTOMAC研究中5年总生存期分析和患者报告结局

讲者：Maria De Santis教授

单位：Department of Urology, Charite Universitaetsmedizin Berlin

03
前列腺癌领域

摘要号：108

英文标题：An Al-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304).

中文标题：来自 ENZAMET (ANZUP 1304) 的基于人工智能的病理分类器，用于预测转移性激素敏感性前列腺癌患者从恩扎卢胺治疗中获益的情况

讲者：Sebastian R. Medina教授

单位：Wallace H. Coulter Department of Biomedical Enaineering at Georaia Tech and Emory University Atlanta

摘要号：5000

英文标题：Clinico-transcriptomic risk stratification to guide abiraterone treatment intensification high-risk prostate cancer：A combined analysis of NRG/RTOG 9202, 9413, 9902, and 0521.

中文标题：临床转录组风险分层指导阿比特龙强化治疗高危前列腺癌：NRG/RTOG 9202、9413、9902和0521的联合分析

讲者：Krishnan R. Patel教授

单位：Radiation Oncoloqy Branch, National Cancer Institute, National Institutes of Health

摘要号：5001

英文标题：Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ)： Level 1B evidence from the ENZAMET study

中文标题：评估Decipher前列腺基因组分类器 (DGC) >0.85识别从多西他赛联合雄激素剥夺疗法和恩扎卢胺中获益的患者的能力：来自ENZAMET研究的1B级证据

讲者：Christopher Sweeney教授

单位：South Australian Immunogenomics Cancer Institute, Adelaide University

摘要号：5002

英文标题：Spatial transcriptomics-guided computational pathology model to stratify docetaxel benefit in metastatic hormone-sensitive prostate cancer： CHAARTED trial (ECOG-ACRIN E3805).

中文标题：空间转录组学指导的计算病理学模型用于对转移性激素敏感性前列腺癌的多西他赛获益进行分层：CHAARTED试验（ECOG-ACRIN E3805）

讲者：Md Mamunur Rahaman,教授

单位：School of Computer Science and Engineering, University of New South Wales

摘要号：5004

英文标题：A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/ Alliance A032101).

中文标题：一项针对转移性激素敏感性前列腺癌患者，在对雄激素受体通路抑制剂反应异常的治疗中中断雄激素剥夺疗法的2期试验（A-DREAM/ Alliance A032101）

讲者：Atish D. Choudhury教授

单位：Dana-Farber Cancer Institute

摘要号：5005

英文标题：Cognitive effects of darolutamide vs enzalutamide. Results of ARACOG (ACT-47, a randomized clinical trial from the Alliance for Clinical Trials in Oncology.

中文标题：达罗他胺与恩扎卢胺的认知效应：ARACOG（ACT-47）的结果，一项肿瘤临床试验联盟的随机临床试验

讲者：Alicia K. Morgans教授

单位：Dana-Farber Cancer Institute, Harvard Medical School

摘要号：5006

英文标题：Final results from ZZFIRST： A randomized phase 2 trial of enzalutamide (EZ) and talazoparib (TALA) in metastatic hormone-naive prostate cancer (mHNPC).

中文标题：ZZFIRST的最终结果：一项针对转移性激素敏感前列腺癌的恩扎卢胺和他拉唑帕利的随机2期试验

讲者：Joaquin Mateo教授

单位：Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron

摘要号：LBA5007

英文标题：TALAPRO-3：Talazoparib (TALA) + enzalutamide (ENZA)compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations.

中文标题：TALAPRO-3：他拉帕唑利+恩扎卢胺对比安慰剂+恩扎卢胺治疗携带同源重组修复基因改变的转移性去势敏感性前列腺癌患者的疗效

讲者：Neeraj Agarwal教授

单位：Huntsman Cancer Institute (NCI-CCC), University of Utah

摘要号：5008

英文标题：Fuzuloparib combined with abiraterone acetate and prednisone (AA-P) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC)： Interim results from the FUZUPRO trial.

中文标题：氟唑帕利联合醋酸阿比特龙和泼尼松作为转移性去势抵抗性前列腺癌的一线治疗：FUZUPRO试验的中期结果

讲者：叶定伟教授

单位：复旦大学附属肿瘤医院

摘要号：LBA5009

英文标题：Safety and dosimetry of 177Lu-rosopatamab tetraxetanplus SoC in patients with metastatic castration-resistant prostate cancer： Preliminary results from part 1 of phase 3 ProstACT Global study.

中文标题：177Lu-rosopatamab tetraxetan联合标准治疗在转移性去势抵抗性前列腺癌患者中的安全性和剂量学：ProstACT Global 3期研究第1部分的初步结果

讲者：Pedro C. Barata教授

单位：University Hospitals Seidman Cancer Center

摘要号：5010

英文标题：AcTION： Phase 1 study of [225Ac]Ac-PSMA-617 (225Ac-PSMA-617) in men with metastatic castration-resistant prostate cancer (mCRPC) with or without prior [177LulLu-PSMA (177Lu-PSMA) radioligand therapy (RLT).

中文标题：AcTION：225Ac-PSMA-617在转移性去势抵抗性前列腺癌男性患者中的1期研究，无论其之前是否接受过[177Lu-PSMA]放射性配体治疗

讲者：Louise Emmett教授

单位：Kinghorn Cancer Centre, St Vincent's Hospital, Sydney

摘要号：5011

英文标题：CONVERGE -01 part 3： Ac-225 rosopatamab tetraxetan (CONV01-a) in Lu-PSMA-pretreated metastatic castrationresistant prostate cancer(mcRPC)

中文标题：CONVERGE-01 第 3 部分：Ac-225 rosopatamab tetraxetan (CONV01-a) 在Lu-PSMA经治的转移性去势抵抗性前列腺癌中的应用

讲者：Michael J. Morris教授

单位：Memorial Sloan Kettering Cancer Center

摘要号：LBA5012

英文标题：Early results of COMPPARE, a prospective comparison of outcomes with proton and photon radiation in prostate cancer.

中文标题：COMPPARE的早期结果：这是一项前瞻性研究，旨在比较质子和光子放射治疗前列腺癌的疗效

讲者：待定

单位：待定

摘要号：5013

英文标题：Genomic classifier-driven NCCN risk reclassification to track distinct transcriptomic signatures in early prostate cancer.

中文标题：基因组分类驱动的NCCN风险重新分类，用于追踪早期前列腺癌中不同的转录组特征

讲者：Daniel Keizman教授

单位：Tel Aviv Sourasky Medical Center

摘要号：5014

英文标题：A phase ,first in human (FIH) study evaluating the safety,Pharmacokinetics, and efficacy of ABBV-969 in patents with metastatic castration resistant prostate cancer (mCRPC)

中文标题：一项首次人体试验研究评估了ABBV-969在转移性去势抵抗性前列腺癌患者中的安全性、药代动力学和疗效

讲者：Tanya B. Dorff教授

单位：City of Hope Comprehensive Cancer Center

摘要号：5015

英文标题：Phase 2 study of YL201,an ant- B7H3 antibody-drug conjugate (ADC), in heavily pretreated metastatic castrationresistant prostate cancer (mCRPC)

中文标题：YL201（一种抗B7H3抗体偶联药物）在接受过多线治疗的转移性去势抵抗性前列腺癌 (mCRPC) 患者中的II期研究

讲者：叶定伟教授

单位：复旦大学附属肿瘤医院

摘要号：5016

英文标题：Phase 2 muticenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP).

中文标题：针对神经内分泌或侵袭性变异转移性前列腺癌患者的化疗免疫疗法的2期多中心试验 (CHAMP)

讲者：Andrew J. Armstrong教授

单位：Division of Medical Oncology, Duke University Medical Center, Duke Cancer Institute, Duke University

摘要号：5017

英文标题：PROTRACT： A randomized phase IIl trial comparing ctDNA-guided biomarker directed therapy vs patient/clinician's choice for metastatic castration resistant prostate cancer (mCRPC) progressing after abiraterone plus prednisone (AAP).

中文标题：PROTRACT：一项随机III期试验比较了ctDNA指导的生物标志物定向治疗与患者/临床医生选择的治疗方案，用于治疗在阿比特龙加泼尼松治疗后进展的转移性去势抵抗性前列腺癌

讲者：Corinne Maurice-Dror教授

单位：BC Cancer - Vancouver Centre, Vancouver

摘要号：5018

英文标题：Circulating tumor DNA-based clinical-genetic (CG) prognostic model for radiographic progression-free survival (rPFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)： Analysis of Alliance A031201.

中文标题：基于循环肿瘤DNA的临床遗传预后模型用于转移性去势抵抗性前列腺癌（mCRPC）患者的放射学无进展生存期（rPFS）：Alliance A031201的分析

讲者：Susan Halabi教授

单位：Department of Brostatistics and Bioinformaties, Duke Cancer Instute center for Prostate and Urologice Cancers, Duke Universty School of Medicne

摘要号：5019

英文标题：Canadian Cancer Trials Group (CCTG) study PR21 (PLUDO)： Results of crossover treatment from a randomized trial of 177Lu-PSMA-617 (LuP) vs docetaxel (DOC) in patients with metastatic castration-resistant prostate cancer (mCRPC).

中文标题：加拿大癌症试验组 (CCTG) PR21 (PLUDO)研究：177Lu-PSMA-617对比多西他赛治疗转移性去势抵抗性前列腺癌患者的随机试验交叉治疗结果

讲者：Kim N. Chi教授

单位：University of British Columbia, BC Cancer, Vancouver Cancer Centre, Vancouver

摘要号：5020

英文标题：Subgroup analyses by disease volume and de novo/recurrent mHSPC in the PSMAddition study of [177Lu]lLu-PSMA-617.

中文标题：在177Lu-PSMA-617的PSMAddition研究中，按疾病体积和新发/复发性mHSPC进行亚组分析

讲者：Fred Saad教授

单位：Centre Hospitalier de I'Universite de Montreal, University of Montreal, Montreal

04
其他瘤种

摘要号：LBA5003

英文标题：First interim analysis of SWOG S1823： Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.

中文标题：SWOG S1823的首次中期分析：循环microRNA 371a-3p (miR371)在预测早期睾丸癌患者的活性生殖细胞恶性肿瘤中的运行特征

讲者：Lucia Nappi教授

单位：BC Cancer Vancouver Centre and Vancouver Prostate Centre, Vancouver

摘要号：4515

英文标题：Phase lstudy of frontine gemctabine,5-fuorouracilleucovorih, and cisplatn (GemFLP) In advanced urachal and non urachalurinary tract adenocarcinoma.

中文标题：吉西他滨、5-氟尿嘧啶和顺铂（Gem FLP）治疗晚期脐尿管和非脐尿管泌尿道腺癌的I期研究

讲者：Emanuele Crupi教授

单位：Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center

（来源：ASCO官网）

声 明

凡署名原创的文章版权属《肿瘤瞭望-泌尿时讯》所有，欢迎分享、转载（开白可后台留言）。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

温馨提示

添加小助手请备注“泌尿”